Vadacabtagene leraleucel

凡基仑赛

Report date: 2026/01/15 10:00:07

Base Information

Drug NameVadacabtagene leraleucel
Drug Alias Name19-28z CAR T cells19-28z+ T cellsJCAR-015JCAR-1519-28z-T-Cells
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vector
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesItaly +[8] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesFred Hutchinson Cancer Research CenterJuno Therapeutics IncMemorial Sloan Kettering Cancer Center +[4] 
China Registration ClassN/A

Develop Information

Active CompaniesMemorial Sloan Kettering Cancer Center
Inactive CompaniesCelgene CorpJuno Therapeutics Inc
Active IndicationsLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A